The Disease Burden of Patients with Allergic Rhinitis from a Hospital Surveillance in Beijing
AbstractBackground: The aims of this study are to estimate the disease burden of allergic rhinitis (AR) patients and examine various underlying issues related to the symptoms and services of adult AR patients. Methods: Beijing hospital was picked as the surveillance area, and self-report questionnaires from the AR patients and data from medical examinations by specialists of otolaryngology were collected. The burden of patients with AR was evaluated by the combined results from patient-questionnaires and specialist examination reports. Results: AR imposed a substantial burden on patients regarding everyday life limitations and work performance; AR affected patients’ noses, ears, throats, and eyes in various ways. The basic daily average medicine cost was 10 RMB for each patient, and the cost for an outpatient in the hospital was 10 RMB for a basic nasal examination and more than 200 RMB if the patient needed further physical examinations. Conclusions: AR imposed burdens on everyday activities and work performance; the patients needed to wait a long time before being diagnosed, and the costs of diagnosis and treatment imposed economic burden on patients. View Full-Text
Share & Cite This Article
Zhang, F.; Nie, C.; Wang, L.; Rosenberg, M.; Xu, J.; Krafft, T.; Wang, W. The Disease Burden of Patients with Allergic Rhinitis from a Hospital Surveillance in Beijing. Sustainability 2017, 9, 427.
Zhang F, Nie C, Wang L, Rosenberg M, Xu J, Krafft T, Wang W. The Disease Burden of Patients with Allergic Rhinitis from a Hospital Surveillance in Beijing. Sustainability. 2017; 9(3):427.Chicago/Turabian Style
Zhang, Fengying; Nie, Chengjing; Wang, Li; Rosenberg, Mark; Xu, Jin; Krafft, Thomas; Wang, Wuyi. 2017. "The Disease Burden of Patients with Allergic Rhinitis from a Hospital Surveillance in Beijing." Sustainability 9, no. 3: 427.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.